You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Claims for Patent: 6,235,883

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,235,883

Title:	Human monoclonal antibodies to epidermal growth factor receptor
Abstract:	In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
Inventor(s):	Jakobovits; Aya (Menlo Park, CA), Yang; Xiao-Dong (Palo Alto, CA), Gallo; Michael (San Jose, CA), Jia; Xiao-Chi (San Mateo, CA)
Assignee:	Abgenix, Inc. (Fremont, CA)
Application Number:	08/851,362
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,235,883
Patent Claims:	1. An isolated antibody that is capable of binding epidermal growth factor receptor comprising a heavy chain variable region comprising a contiguous sequence from CDR1 through CDR3 as represented in SEQ ID NO:23. 2. The antibody of claim 1, further comprising a light chain variable region comprising the sequence represented by SEQ ID NO:24. 3. An isolated antibody that is capable of binding epidermal growth factor receptor comprising a heavy chain variable region comprising a contiguous sequence from CDR1 through CDR3 as represented in SEQ ID NO:25. 4. The antibody of claim 3, further comprising a light chain variable region comprising the sequence represented by SEQ ID NO:26. 5. An isolated antibody that is capable of binding epidermal growth factor receptor comprising a heavy chain variable region comprising a contiguous sequence from CDR1 through CDR3 as represented in SEQ ID NO:27. 6. The antibody of claim 5, further comprising a light chain variable region comprising the sequence represented by SEQ ID NO:28. 7. An isolated antibody that is capable of binding epidermal growth factor receptor comprising a heavy chain variable region comprising a contiguous sequence from CDR1 through CDR3 as represented in SEQ ID NO:29. 8. The antibody of claim 7, further comprising a light chain variable region comprising the sequence represented by SEQ ID NO:30. 9. An isolated antibody that is capable of binding epidermal growth factor receptor comprising a heavy chain variable region comprising a contiguous sequence from CDR1 through CDR3 as represented in SEQ ID NO:31. 10. The antibody of claim 9, further comprising a light chain variable region comprising the sequence represented by SEQ ID NO:32. 11. An isolated antibody that is capable of binding epidermal growth factor receptor comprising a heavy chain variable region comprising a contiguous sequence from CDR1 through CDR3 as represented in SEQ ID NO:33. 12. The antibody of claim 11, further comprising a light chain variable region comprising the sequence represented by SEQ ID NO:34. 13. An isolated antibody that is capable of binding epidermal growth factor receptor comprising a heavy chain variable region comprising a contiguous sequence from CDR1 through CDR3 as represented in SEQ ID NO:35. 14. The antibody of claim 13 further comprising a light chain variable region comprising the sequence represented by SEQ ID NO:36. 15. An isolated antibody that is capable of binding epidermal growth factor receptor comprising a heavy chain variable region comprising a contiguous sequence from CDR1 through CDR3 as represented in SEQ ID NO:37. 16. The antibody of claim 15, further comprising a light chain variable region comprising the sequence represented by SEQ ID NO:38.

Details for Patent 6,235,883

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	September 27, 2006	⤷ Subscribe	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 6,235,883

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9850433	⤷ Subscribe
United States of America	8227580	⤷ Subscribe
United States of America	7807798	⤷ Subscribe
United States of America	2010305307	⤷ Subscribe
United States of America	2006183887	⤷ Subscribe
United States of America	2005100546	⤷ Subscribe
United States of America	2002173629	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.